An update from InnoCare Pharma Ltd. ( (HK:9969) ) is now available.
InnoCare Pharma Ltd. announced positive phase II clinical trial results for orelabrutinib, a treatment for relapsing-remitting multiple sclerosis (RRMS), at the ACTRIMS Forum 2025. The trial demonstrated that the 80 mg once daily dose of orelabrutinib significantly reduced new brain lesions in RRMS patients, showing a 90.4% reduction at 12 weeks and 92.3% at 24 weeks compared to placebo. This advancement positions InnoCare as a key player in the MS treatment landscape, potentially impacting its market presence and offering hope for improved patient outcomes.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company focused on developing innovative treatments in the field of neuroimmunology, particularly targeting multiple sclerosis and related disorders. The company is known for its research and development of highly selective, brain-penetrant BTK inhibitors.
YTD Price Performance: 26.80%
Average Trading Volume: 5,144,848
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$11.61B
For an in-depth examination of 9969 stock, go to TipRanks’ Stock Analysis page.